Diabetes charity Diabetes UK has linked up with Bristol-Myers Squibb and AstraZeneca to launch a nationwide patient survey. The aim of the study is to find out more about hypoglycaemia . Together, the pharmaceutical companies will start to market a type 2 diabetes drug called Onglyza later on this year.
The patient survey is timed to fit in with Diabetes Week next week. Chief Executive of Diabetes UK, Douglas Smallwood, reportedly commented: “Although we already know a lot about severe hypoglycaemia, little has been done to investigate mild-to-moderate episodes, which people can experience on a regular basis.”
The medical director of Astrazeneca UK, Dr. Yeoma, was meanwhile reported in the media as saying: “We hope the results of the survey will raise the understanding and awareness of mild-to-moderate hypos and lead to the improved management of type II diabetes across the UK.”

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Coronavirus: UK instructed to stay at home this weekend

Health Secretary Matt Hancock has said that staying at home this weekend…

Conversation about doctors’ appointments occurring virtually rumbles on

More than half of GP appointments are still being delivered remotely in…

Public Health England considers low carb approach for type 2 diabetes

The low carb approach is being considered by the government to be…